In the News

October 27, 2022
Contagion Live
Cefepime-Taniborbactam Beats Meropenem for Treating cUTI in Phase 3 Trial
Venatorx Pharmaceuticals announced successful phase 3 trial results for cefepime-taniborbactam, its investigational antibiotic aimed at treating complicated urinary tract infections.
May 24, 2022
The Hill
Antibiotic Resistance: A Looming Public Health Crisis
What threats do antibiotic-resistant superbugs pose for the future? What is being done to develop new antibiotics and bring life-saving drugs to market? And how can policymakers stimulate innovative drug developments to keep pace with evolving diseases?
April 4, 2022
STAT News
Pharma’s ambitious new antibiotic venture fund makes its first investments
One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.
April 4, 2022
PharmaPhorum
Pharma-backed antibiotic fund makes first investments
AMR Action Fund said this morning that the first two beneficiaries are Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals, two biotechs that according to AMR Action Fund chief executive Henry Skinner “are poised to change the treatment landscape for drug-resistant infections.”
April 4, 2022
Reuters
Pharma industry-backed fund invests in two biotech companies to treat ‘superbugs’
A $1 billion fund backed by over 20 drugmakers made its first set of investments on Monday in two biotechnology startups to help struggling antibiotic makers tackle the threat of antibiotic-resistant bacteria.
April 4, 2022
Wall Street Journal
Antibiotics Venture Fund Makes Its First Two Investments
A fund that plans to invest $1 billion in antibiotics companies has made its first two deals, backing startups aiming to tackle AMR in different ways. AMR Action Fund launched in 2020 to finance smaller biotechnology companies with antimicrobial drugs in clinical trials, bridging what it says is a funding gap between early research and regulatory approval.
April 4, 2022
Bloomberg
Pharma-Backed Fund Makes First Investments in Superbug Fight
A $1 billion fund backed by some of the world’s biggest drugmakers has made its first two investments in a bid to spur the development of new antibiotics and counter the rising threat of superbugs.
April 4, 2022
Endpoint News
AMR Action Fund looks to tackle antimicrobial resistance with first two investments — but does the money arrive too late?
The AMR Action Fund has made its first two investments in the hopes of addressing the looming threat of antimicrobial resistance.
April 4, 2022
FinSMEs
Venatorx Pharmaceuticals Raises Series C Financing
Venatorx Pharmaceuticals sold shares of its Series C Preferred Stock in a financing of undisclosed amount. Proceeds from the financing will be used to support the company as it advances its novel antibacterial portfolio through the drug development process.
April 4, 2022
CIDRAP
AMR Action Fund announces its first investments
The two companies represent different approaches to combating antimicrobial resistance (AMR). One is a more traditional antibiotic approach, while the other actually predates antibiotics.
April 4, 2022
Healio | Infectious Disease News
$1 billion fund seeking new antibiotics targets phages with first investments
A $1 billion public-private partnership seeking new antibiotics announced its first investments. The AMR Action Fund said it has invested in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.
April 4, 2022
FierceBiotech
Big Pharma-backed $1B AMR Action Fund picks 1st antimicrobial biotech investments
The AMR Action Fund, backed by Big Pharmas such as Pfizer, Eli Lilly, Bayer and more, has selected the first beneficiaries of its $1 billion fund to address drug-resistant bacterial infections: Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.
March 14, 2022
Medical Dialogues
Cefepime and Taniborbactam Combo Better Than Meropenem for Complicated UTI
Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections, including acute pyelonephritis.
March 14, 2022
FDA News
Venatorx’s Combination Antibiotic Will Head to FDA
Armed with positive phase 3 data, Venatorx Pharmaceuticals will ask regulators to approve its investigational combination antibiotic, cefepime-taniborbactam, as a treatment for complicated urinary tract infections (cUTI) in adults.
March 12, 2022
AMR Insights
Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI
Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.
March 11, 2022
pharmaphorum
Venatorx plans new antibiotic filing after phase 3 readout
Venatorx Pharmaceuticals has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of antimicrobial resistance.
March 10, 2022
Philadelphia Business Journal
Venatorx reports positive clinical study results for its experimental antibiotic
A Chester County pharmaceutical company on Thursday announced positive results for its lead new drug candidate, an antibiotic under development to treat complicated urinary tract infections.
March 10, 2022
ContagionLive
Venatorx Pharmaceuticals Reports Positive Results for its Investigational Antibiotic for cUTI
Complicated Urinary Tract Infections can be very challenging for clinicians to treat. These UTI do not respond to traditional, first-line therapies, and due to the nature of these bacterial infections, and patients' frequent underlying health conditions, they can be more susceptible to complications including sepsis.
March 10, 2022
BioSpace
Venatorx Scores Victory over AMR in Phase III UTI Study
Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.
March 10, 2022
FierceBiotech
Venatorx hits goal in antibiotic phase 3, clearing path to FDA
Venatorx Pharmaceuticals’ mission to start restocking the thinning cupboard of antibiotics has advanced. With its experimental candidate hitting the primary endpoint in phase 3, Venatorx is preparing to file for FDA approval in patients with urinary tract infections by the end of the year.
Archive: 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
You are using a browser that is not supported. Please consider changing your browser